Bayer, Rad AI partner for AI radiology workflow offering

GenAI Radiology Workflow Company Rad AI and Bayer have announced a collaboration to bring Rad AI technology to the multinational pharmaceutical and biotechnology company’s Calantic Digital Solution customers.

Calantic is a vendor-neutral, cloud-based marketplace of AI-powered radiology applications aimed at automating routine radiology tasks.

California-based Rad AI offers radiologists generative AI tools to help streamline workflows, such as medical dictation and follow-up care management offerings.

One of its offerings is its Rad AI Omni Impressions platform, which generates AI-driven report impressions after a radiologist dictates the raw results. The platform continuously learns the stylistic tone and voice of each radiologist and generates reports with individualized and specific print language.

Rad AI’s AI-based follow-up management, radiology voice recognition reporting and radiology impression generation technologies will be available to Calantic customers.

“Our customers consistently tell us that a clear ROI from using AI will help increase trust and adoption. Demonstrating ROI through operational applications like those in Bayer’s Calantic Digital Solutions platform is often an easier route, which is why Bayer is excited to enter into this agreement with Rad AI,” said Rich Dewit, Vice President senior president of digital solutions at Bayer Radiology, in a statement.

“This technology has the ability to help physicians optimize and streamline their radiology reporting and deliver benefits to the patient and the healthcare system.”

THE MOST GENERAL TREND

Earlier this month, Rad AI announced a partnership with LucidHealth, a national network of radiology practices, which will use its Omni Impressions dictation tool across its community practices.

In January, Rad AI announced a partnership with Google Cloud, which allowed genAI to scale its technology using MedLM core models and Google cloud services.

In May, Rad AI obtained $50 million in Series B funding, bringing its total raised to over $80 million. In 2021, the company secured $25 million in Series A funding.